Clinigen Group plc Rule 2.9 Announcement (2755R)
September 20 2017 - 5:07AM
UK Regulatory
TIDMCLIN
RNS Number : 2755R
Clinigen Group plc
20 September 2017
20 September 2017
Rule 2.9 Announcement
In accordance with Rule 2.9 of the City Code on Takeovers and
Mergers, Clinigen Group plc (the "Company") confirms that, as at
the date of this announcement, its issued share capital consists of
115,165,344 ordinary shares 0.1 pence each with International
Securities Identification Number GB00B89J2419. The Company holds no
shares in treasury.
-Ends-
Contact details
Clinigen Group plc Tel: +44 (0) 1283
495010
Shaun Chilton, Group Chief
Executive Officer
Martin Abell, Group Chief
Financial Officer
Numis Securities Limited Tel: +44 (0) 20
7260 1000
Michael Meade / Freddie Barnfield
(Nominated Adviser)
James Black / Tom Ballard
(Corporate Broking)
RBC Capital Markets - Joint Tel: +44 (0) 20
Broker 7653 4000
Marcus Jackson / Elliot Thomas
/ Jack Wood
Instinctif Partners Tel: +44 (0) 20
7457 2020
Adrian Duffield / Melanie
Toyne-Sewell / Alex Shaw Email: clinigen@instinctif.com
About Clinigen Group
Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and
services company with a unique combination of businesses focused on
providing access to medicines. Its mission is to deliver the right
medicine to the right patient at the right time through three areas
of global medicine supply; clinical trial, unlicensed and licensed
medicines.
For more information, please visit www.clinigengroup.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
RTTEANNEAESXEEF
(END) Dow Jones Newswires
September 20, 2017 05:07 ET (09:07 GMT)
Clinigen (LSE:CLIN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Clinigen (LSE:CLIN)
Historical Stock Chart
From Sep 2023 to Sep 2024